Skip to main content
OpenTrials
Completed

NCT Number: NCT00364104

Helicobacter Pylori Eradication Trial to Reduce Iron Deficiency in Children

The investigators hypothesize that the Helicobacter pylori bacterium decreases iron from the stomach and that this effect of the infection can be identified among persons with iron deficiency as well as among persons with normal iron stores. The aim of this study is to determine whether Helicobacter pylori eradication in children is followed by an increase in markers of iron stores after six to twelve months of treatment.

Completed

Looking for future studies?

Notify Me

Key information

Age range

36 month–120 month

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Primary location

Texas Tech University School of Medicine

El Paso, Texas, 79905, United States

About this study

For the last 12 years, scientific evidence has mounted linking Helicobacter pylori infection with iron deficiency and iron deficiency anemia. Reports from around the world on several cases of iron deficiency anemia refractory to iron supplementation among children infected with Helicobacter pylori, most without evident ulcers, clearly indicate that such cases have been cured of their anemia after receiving a course of Helicobacter pylori eradication therapy. Several studies based on national surveys, including one on the U.S. National Health and Nutrition Examination Survey data and conducted by the authors of this proposal, have found an association between Helicobacter pylori infection and the levels of iron stores. However, these studies fail to demonstrate that anemia follows Helicobacter pylori infection. Moreover, most previous research has been conducted outside of the contiguous U.S. and has not included young children, one of the high-risk populations for iron deficiency and iron deficiency anemia. Data on this age-group is most needed to develop sound public health interventions.

We propose to conduct such a study among children living in El Paso, Texas, a city located on the U.S.-Mexico border. A series of studies have been conducted in that city by the authors of this proposal, including a National Institutes of Health sponsored study aiming to describe the natural history of Helicobacter pylori infection in children from birth to age seven years (84 months). We hypothesize that the Helicobacter pylori bacterium decreases iron from the stomach and that this effect of the infection can be identified among persons with iron deficiency as well as among persons with normal iron stores. Currently, the clinical management of the most extreme form of iron deficiency, that is iron deficiency anemia, relies only on supplemental iron therapy. For ethical reasons, our study will identify children with anemia from the study, and will assign them to one of the arms receiving iron supplementation. Our study will determine whether a combination of iron supplementation and sequential Helicobacter pylori eradication therapy yields higher increases of iron stores than each of these treatments alone. To summarize, our main hypothesis is that Helicobacter pylori infection is associated with iron deficiency such that Helicobacter pylori eradication would result in an increase in the levels of:

  • serum ferritin,
  • transferrin saturation, and
  • hemoglobin.

To test these hypotheses we will randomly assign 125 Helicobacter pylori-infected children (3 to 10 years of age) into each of the following four groups: Helicobacter pylori eradication treatment, iron supplementation, Helicobacter pylori eradication plus iron supplementation, or placebo. We plan to recruit infected children through a household survey in El Paso, screen their Helicobacter pylori infection status by a stool test, and invite their parents to undergo a confirmatory breath test. Infected children randomly allocated to those four arms of the study will be followed closely during the 6 weeks they are taking the study medication to record any adverse event, followed by a visit at 45 days after treatment to tell whether or not those receiving the medication had their infection eradicated, between 6 and 12 months for hematological evaluation to compare with the baseline levels of iron stores.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Children 3-10 years of age
  • Helicobacter pylori infected, asymptomatic
  • Healthy otherwise
  • Parents provided consent/assenting children 7-10 years of age

Exclusion criteria

  • Parental consent or child assent not obtained
  • History of antibiotic-related allergic episodes
  • Children with a history of allergy, asthma, hay fever or urticaria
  • Phenylketonurics
  • Abnormal renal and hepatic functions as evaluated through albumin, bilirubin, AST (or SGOT), ALT (or SGPT), alkaline phosphatase and GGT-P
  • History of peptic ulcer
  • History of recent (< 1 month) severe disease
  • History of recent (< 1 month) use of antibiotics, antacids, H2 receptor antagonists, proton pump inhibitors and remedies containing bismuth
  • Parents uncertain about staying in El Paso for the next year

Treatment and study plan

Quadruple sequential Helicobacter pylori eradication + iron sulfate

Drug

A 10-day course of Hp infection sequential eradication therapy plus 6-weeks of iron supplementation

Quadruple sequential Helicobacter pylori eradication therapy

Drug

A 10-day course of Hp infection sequential eradication therapy only plus 6-weeks of matching placebo of iron supplementation

Ferrous Sulfate

Drug

6-weeks of iron supplementation only plus 10-days matching placebo of Hp infection eradication therapy

Placebo

Drug

Placebo only (10-days of matching placebo of Hp eradication therapy and 6-weeks of matching iron supplementation).

Primary outcomes

  1. Percent change of serum ferritin

    Time frame: between 6 and 12 months

  2. Percent change of transferrin saturation

    Time frame: between 6 and 12 months

  3. Percent change of hemoglobin

    Time frame: between 6 and 12 months

Secondary outcomes

  1. Proportion of children who cleared their H. pylori infection

    Time frame: 45+ days after completing treatment

Sponsors and collaborators

Lead sponsor

The University of Texas Health Science Center, Houston

Other

Collaborators

  • Baylor College of Medicine
  • Texas Tech University
  • University of North Texas Health Science Center
  • University of Texas

Registry information

Official study title

Randomized Field Intervention Trial of H. Pylori Eradication to Reduce Iron Deficiency Among Children in El Paso, Texas

Acronym: HEIDC

Important dates

Study start
2007
Primary completion
2008
Study completion
2008
First posted
Aug 15, 2006
Registry last updated
Jun 30, 2009

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.